Evidence map›Paper›PMID 37745862›Full record

ArticleFrontiers in genetics2023

Establishing induced pluripotent stem cell lines from two dominant optic atrophy patients with distinct

Katherine A Pohl, Xiangmei Zhang, Anh H Pham, Jane W Chan, Alfredo A Sadun, Xian-Jie Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Katherine A PohlDepartment of Ophthalmology, Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, United States.
Xiangmei ZhangDepartment of Ophthalmology, Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, United States.
Anh H PhamDepartment of Ophthalmology, Doheny Eye Institute, University of California, Los Angeles, Pasadena, CA, United States.
Jane W ChanDepartment of Ophthalmology, Doheny Eye Institute, University of California, Los Angeles, Pasadena, CA, United States.
Alfredo A SadunDepartment of Ophthalmology, Doheny Eye Institute, University of California, Los Angeles, Pasadena, CA, United States.
Xian-Jie YangDepartment of Ophthalmology, Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, United States.
University of California, Los Angeles · US

Funding

Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVID S WILLIAMS · 1985 to 2026
$16.8M
Vision Science Training ProgramT32EY007026 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Alapakkam P Sampath · 1985 to 2026
$5.7M
Neuroprotection Mechanism for PhotoreceptorsR01EY026319 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, XIAN-JIE · 2016 to 2025
$4.1M
Understanding OPA1 mutation-driven dominant optic atrophy using human PSC-derived retinal ganglion cellsF31EY033242 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POHL, KATHERINE ANNE · 2021 to 2022
$88k
NEI NIH HHS F31 EY033242NEI NIH HHS P30 EY000331NEI NIH HHS R01 EY026319NEI NIH HHS T32 EY007026
6 · The paper itself

Abstract

Dominant optic atrophy (DOA) is an inherited disease that leads to the loss of retinal ganglion cells (RGCs), the projection neurons that relay visual information from the retina to the brain through the optic nerve. The majority of DOA cases can be attributed to mutations in

Indexed as

DOAdominant optic atrophyinduced pluripotent stem cells (iPSC)OPA1retinal ganglion cellRGC

Identifiers

PMID37745862
PMCPMC10513078
OpenAlexW4386418001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.